Montreuil

Dialysis patients often face reduced walking ability and a higher risk of high blood pressure, which can lower their quality of life and increase mortality. Researchers are studying whether physical activity performed during dialysis sessions can improve quality of life, muscle health, cardiovascular status, and dialysis-related parameters in these patients. The study aims to clarify the benefits of exercise during dialysis, especially in patients who can regularly participate. Participants will engage in physical activity while undergoing their usual dialysis treatments. This intervention involves exercising during dialysis sessions to assess its impact on various health factors. The study focuses on patients who are compliant and able to perform physical activity during these sessions. No other treatments or comparison groups are mentioned. During the study, researchers will monitor changes in the participants' quality of life over 17 weeks. They will also evaluate muscle strength, biological markers, and dialysis parameters to understand how exercise affects these areas. Participants will be assessed through clinical evaluations and monitored for safety throughout the study period.

Researchers are investigating the effects of preoperative immunomodulation using Oral Impact®, a nutrient-enriched dietary supplement, on reducing postoperative complications in patients undergoing major urological surgeries such as cystectomies and nephrectomies. While Oral Impact® has shown benefits in gastrointestinal, ENT, gynecological, and cardiac surgeries by modulating immune and inflammatory responses, evidence in major urological surgery is currently lacking. This study aims to evaluate whether Oral Impact® can decrease complications and shorten hospital stays in this specific patient group, addressing issues related to malnutrition and surgical stress. Participants will be divided into two groups: one group will receive a 7-day course of Oral Impact® before surgery, while the control group will not receive any intervention. The study focuses on the preoperative period to improve patients' nutritional and immune status to better handle surgical stress. The use of Oral Impact® includes immune-modulating nutrients such as arginine, omega-3 fatty acids, nucleic acids, vitamins, and antioxidants. Postoperative management may include nutritional rehabilitation and, if necessary, supplementation with 20% reduced albumin to correct hypoalbuminemia. During the study, patients will be monitored for major postoperative complications over a 3-month period. Assessments will include clinical evaluations, nutritional status, and length of hospital and ICU stays. Researchers will track complications related to immune deficiency, infections, and recovery progress. The goal is to measure the rate of major postoperative complications and understand the potential benefits of preoperative Oral Impact® immunomodulation in urological surgery patients.

Researchers are evaluating whether giving amiodarone for 72 hours can reduce the risk of death or severe dangerous heart rhythms in critically ill patients admitted after an out-of-hospital cardiac arrest with a shockable heart rhythm and a confirmed or suspected cardiac cause. This phase 3 study focuses on improving outcomes within 30 days after treatment starts, addressing a critical period following cardiac arrest where complications are common. Participants receive an initial 300 mg loading dose of amiodarone over 30 minutes in a glucose solution, followed by a continuous infusion for 72 hours at a dose of 10 mg/kg per day, not exceeding 900 mg in 24 hours. The treatment is given through a central venous catheter in the intensive care unit. The study compares this preventive approach to standard care to see if it lowers the chance of death or severe ventricular arrhythmias requiring urgent intervention. During the study, participants are closely monitored in the ICU with regular assessments to track heart rhythms and overall health status. Researchers measure the rate of mortality and severe ventricular arrhythmias within 30 days from the start of treatment. Safety and treatment effects are carefully observed during this critical period to determine if prophylactic amiodarone can improve patient outcomes after cardiac arrest.

This research aims to understand how doctors decide when extremely premature infants, born before 28 weeks of gestational age, are ready to be taken off mechanical ventilation in the first two weeks of life. The study explores doctors' views on extubation readiness, reasons for extubation or continuing ventilation, and how these decisions relate to successful extubation, defined as not needing reintubation within seven days. It also investigates which factors, including clinical status and ventilator settings, are linked to readiness for extubation and outcomes like respiratory health. The study collects daily data from attending physicians who complete questionnaires about their decisions to extubate or not during the first 15 days of life for infants on mechanical ventilation. No experimental treatments are given, as this is an observational study conducted across several neonatal intensive care units in France. The research focuses on routine clinical care and tracks respiratory support practices during the newborns' hospital stay. Participants' health details, respiratory outcomes, and survival are recorded until they are discharged or no longer need any breathing support or oxygen. Researchers monitor reasons for continued ventilation or extubation attempts every 12 hours for the first two days and daily up to day 15. This detailed data collection helps understand extubation practices and outcomes in extremely premature infants.